User Guideline

MREC Reviewer

National Medical Research Register v2.0

National Institutes of Health (NIH)

Version 1.0, April 2022

Table of Contents

1.0 – Flow & Function of MREC Reviewer	1
1.1 - As MREC Reviewer (Submission Review)	1
1.2 – Meeting Attendance	8

1.0 – Flow & Function of MREC Reviewer

1.1 - As MREC Reviewer (Submission Review)

- 1. Go to the url https://www.nmrr.com
- 2. Login as a necessary individual with an assigned role as MREC Reviewer and the Reviewer page located at the left side.



 Should be able see the submission under the assigned secretariat. (It should be stated as (Undergoing Expedited Review by MREC Chairperson/Deputy Chairperson, Undergoing Expedited Review by MREC Primary Reviewer, Queue for MREC Full Board Review)

bmiss	sion Review A	ppro	val									
eyword						Status						
Search N	MRR ID, Research ID or 1	Title of t	he Submission			Select All						~
EXCEL	PDF Show 10 Research ID	∼ er	ntries NMRR ID	0	Title 🕴	Status	0	Day To Submission	0	Act	ion	

4. Click on the view data (eye icon) to go into that submission details and to review the submission, go into the Processing Submission page (paper icon)

ubmis	sion Review A	pprov	/al									
Keyword							Status					
Search N	NMRR ID, Research ID or	Title of th	e Submission				Select All					~
EXCEL	PDF Show 10 Research ID	∼ en	tries	0	Title	¢	Status	0	Day To Submission	0	Action	

5. Click on the (eye icon) to go into the submission details and to access the checklist and recommendation selection, click the review checklist page (paper icon)

Review Revisions					
EXCEL PDF Show	10 v entries				
# Aevis	sion ID 🔶	Secretariat	Created Date	♦ Acti	on
1 REV I	D-21-00022-MRH	MREC Secretariat	08-09-2021	Ē	© Ů
Showing 1 to 1 of 1 ent	ries				Previous 1 Next

6. Reviewer may choose the status of each item by clicking on the status dropdown

VIEW REPORT OF RESEARCH PROTOCOLS INVOLVING HUMAN SUBJECTS		
O All(55) ○ Yes(0) ○ No(0) ○ Not Relevant(0) ○ Complete(55) ○ Not Complete(0)		
DATA	STATUS	COMMENTS
1. General Information		
1.1 Is study title appropriate?	Complete ~ Yes	¢Q
1.2 Is there a protocol identifying number and date?	No Not Relevant Complete Not Complete	© Q
1.3 is the name and address of sponsor stated?	Complete v	© Q
1.4 Is the name and institution of investigator/s stated?	Complete v	© Q
1.5 Is the study site appropriate in terms of facilities, expertise, patient populations, etc?	Complete ~	¢ Q
1.6 is there sufficient and appropriate expertise and experience in the study team?	Complete v	© Q

7. If there is any query or revision required, click on the comment button to add a comment. Click the "comment button" to enter and save the comment intended for the investigator

All(55) (Yes(0) (No(0) Not Relevant(0) (Complete(55) Not Complete(0)		
мта	STATUS	COMMENTS
General Information		
1 Is study title appropriate?	Complete ~	© Q
.2 Is there a protocol identifying number and date?	No Not Relevant Complete Not Complete	© Q
.3 Is the name and address of sponsor stated?	Complete v	¢ 🤤
.4 Is the name and institution of investigator/s stated?	Complete ~	¢ 🤤
.5 Is the study site appropriate in terms of facilities, expertise, patient populations, etc?	Complete v	© Q
.6 Is there sufficient and appropriate expertise and experience in the study team?	Comelete	80

Comments		×
no complete		
		h
		Comment

8. For minimal risk study (Undergoing Expedited Review by MREC Chairperson/Deputy Chairperson) the reviewer will insert the assessment by filling up the form and click save. If there is any query or revision required, click on the comment button at the "minimal risk overall comment". Click the "comment button" to enter and save the comment intended for the investigator

DATA	STATUS COMMENT
Minimal Risk Overall Comment	~ S
sk Assessment	
REVIEWED BY HRRC/ OTHER SCIENTIFIC REVIEW COMMITTEES	
O Yes	O No
Hospital Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur Vulnerability Assessment	
Study involves vulnerable population	Study involves no vulnerable population
Risk Assessment	
Study involves more than minimal risk (tick below)	Study involves no more than minimal risk
Benefit Assessment	
No prospect of direct benefit to individual participants, but likely to yield generalizable knowledge about the participant' disorder or condition	No prospect of direct benefit to individual participants, but likely to yield generalizable knowledge to further society's understanding or the disorder or condition under study
The research involves the prospect of direct benefit to individual	

9. For other type of review, compilation comments can be seen by clicking the compilation & response icon (green box) next to the comment icon (investigator response later will be displayed after the revision has been submitted by the investigator). The compilation is used during the revision reassignment by the reviewer. Reviewers will be able to see the compilation of comment and investigator answers as below

I) (Is the rationale/justification for the study clearly stated in the context of present knowledge?)	Not Complete v	¢
2) (Does the project address important/relevant scientific/public health issues?)	Not Complete v	¢
3) (Will the proposed research contribute new knowledge in the subject area?)	Not Complete v	¢
Dbjectives Are the objectives and/or hypothesis clearly stated and realistic Specific, Measurable, Achievable, Resourced within the project and Time bound))	Not Complete v	¢
Expected Outcome and Output What are the intended outputs and outcomes?)	Not Complete 🗸	¢ Ç

"Compilation comment made by secretariat"	
"Investigator answers to the query"	
	Canc

10. Grouping of status can be used as a guide to reviewers to see which item are complete, not complete and etc.

DATA	STATUS	COMMENTS
I. General Information		
1.1 Is study title appropriate?	Complete ~	© Q
1.2 Is there a protocol identifying number and date?	No Not Relevant Complete Not Complete	e Q
1.3 Is the name and address of sponsor stated?	Complete v	e Q
1.4 Is the name and institution of investigator/s stated?	Complete v	e Q
1.5 is the study site appropriate in terms of facilities, expertise, patient populations, etc?	Complete ~	5 Q
1.6 Is there sufficient and appropriate expertise and experience in the study team?	Complete v	¢ Q

11. Once the review is complete, the reviewer will then select the recommendation at the end of the checklist. Click the submit button to notify the Secretariat regarding the completion and the recommendation made. (Applicable for all type of review; minimal risk, medium and high-risk study

Reviewer Feedback & Recommendation		
Feedback		
		li li
	Submission Recommendation Unable to review	- 1

12. Once the submit button is clicked, all the status and the recommendation will not be able to be changed.

Miscellaneous		
13.1 Is the grammar and language acceptable?	Complete V	I
13.2 Additional Document & Comment from Reviewers	Complete V 🤤 📿	
eviewer Feedback & Recommendation		
Feedback		
	Submission Recommendation	
	Revision Required, Go back to Secretariat	Ÿ

13. Once all required review is completed, the list of review will be disappeared from the submission review dashboard

Search NMRR ID, Research ID or Title of the Submission			Select All			~	
EXCEL	PDF Show 10	✓ entries	Title	♦ Status	Day To Submission	Action	
#	Research ID	NMRR ID					
#	Research ID	• NMRR ID	No data	available in table			

1.2 – Meeting Attendance

- 1. Go to the url <u>https://www.nmrr.com</u>
- 2. Login as individual (with assigned role as MREC Reviewer either Red or Blue Panel)
- 3. Click on the "Meetings" icon menu selection over the left side of the display page

Ć	National Medical Research Register Advancing Medical Research in Malaysia	
窗	Dashboard	
\$	My Submissions	
₿	My Research	
٢	Approvals	
Ü	Meetings	
SHORTCUT		
Create New Meeting		

4. Select the intended upcoming meeting by clicking on the view (eye) icon present under "action" column

Meetings				
Title -Select All-	Place		Meeting Date dd/mm/yyyy	dd/mm/yyyy
EXCEL PDF Show 10	✓ entries PLACE	MEETING DATE		
Blue Panel	Bilik Mesyuarat Pintar 3, Level 4, Block D2, NIH Setia Alam	2021-10-26	Ø	
Red Panel	Bilik Mesyuarat Pintar 3, Level 4, Block D2, NIH Setia Alam	2021-10-12	0	
Showing 1 to 2 of 2 entries				Previous 1 Next

5. Panels should be able to view the meeting details with all the study list attachment uploaded by Secretariat

Meeting Details	
Meeting Information	
Date of Meeting	2021-10-12
Panel Title	Red Panel
Meeting Place	Bilik Mesyuarat Pintar 3, Level 4, Block D2, NIH Setia Alam
Study List	A Phase 2/3, randomized, double-blind, placebo- controlled study to evaluate the efficacy and safety of orally administered SKF7" (Standardized NMRR ID-21-01963-QGE extract of Labisia pumila) in the clinical improvement of category 3 COVID-19 patients.
Created By	Asyraf Syahmi Bin Mohd Noor

6. Individual attendees for specific panels and other additional people should be able to see their name listed in Attendance Details while selection is displayed to whether they will be "present" or "not able to present"

Meeting Details	
Meeting Information	
Date of Meeting	2021-10-12
Panel Title	Red Panel
Meeting Place	Bilik Mesyuarat Pintar 3, Level 4, Block D2, NIH Setia Alam
Study List	A Phase 2/3, randomized, double-blind, placebo- controlled study to evaluate the efficacy and safety of orally administered SKF7" (Standardized NMRR ID-21-01963-QGE extract of Labisia pumila) in the clinical improvement of category 3 COVID-19 patients.
Created By	Asyraf Syahmi Bin Mohd Noor

tendance Details			
NAME	ROLE	STATUS	
Dr Salina Binti Abdul Aziz	Chair Person	Awaiting Response	Please Select

7. By clicking the attendance selection, upcoming attendance confirmation will be updated to the Secretariat. If panel is unable to attend the upcoming meeting, reason can be stated to notify secretariat regarding the absence.

endance Details			
NAME	ROLE	STATUS	
Dr Salina Binti Abdul Aziz	Chair Person	Awaiting Response	Not Able to Present
Tuan Abdullah	Panel Members	Awaiting Response	
Dr Sondi Sararaks	Panel Members	Awaiting Response	

8. Panel members will be able to see the list of studies that is going to be tabled during the upcoming meeting and documents uploaded (if any) during the meeting. To see the documents and review made by the reviewers assigned for the submission, click on the view (eye) icon while to insert comment related to the submission, click on the comment (paper) icon. All panels present during the meeting will be able to make comments to the study list by clicking on the comment icon in the study list (available only during the meeting day).

Meeting Details	
Meeting Information	
Date of Meeting	2021-10-12
Panel Title	Red Panel
Meeting Place	Bilik Mesyuarat Pintar 3, Level 4, Block D2, NIH Setia Alam
Study List	A Phase 2/3, randomized, double-blind, placebo- controlled study to evaluate the efficacy and safety of orally administered SKF7 [™] (Standardized NMRR ID-21-01963-QGE extract of Labisia pumila) in the clinical improvement of category 3 COVID-19 patients.
Created By	Asyraf Syahmi Bin Mohd Noor